Advances in Renal Bone Disease: Osteoporosis and Chronic Kidney Disease

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2009 Jul 17

PMID 19604462

Citations 4

Authors

Sara Barnato

Stuart M Sprague

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is a common bone disease characterized by low bone density, microarchitectural deterioration of bone tissue, and a consequent increase in fracture risk. Recent decades have seen major advances in the understanding of the pathophysiology, prevention, and treatment of this disorder. Chronic kidney disease (CKD) affects more than 20 million Americans and is associated with unique metabolic mineral disorders related to low bone density and increased fractures. Because many patients with low bone density may have CKD, and the combination of osteoporosis and CKD may further increase fracture risk with increased morbidity and mortality, appropriate identification is necessary for effective management. The clinical, laboratory, and imaging studies currently used to diagnose osteoporosis in the general population inadequately detect the complex bone and metabolic changes that occur with CKD. This review focuses on the pathophysiology of osteoporosis and CKD and discusses problems with current diagnostic tools and considerations for treatment regimens.

Citing Articles

Alterations in the Mineral Bone Metabolism of Living Kidney Donors After Uni-Nephrectomy: Prospective Observational Study.

Lee H, Eum S, Ko E, Cho H, Yang C, Chung B Front Med (Lausanne). 2021; 8:741944.

PMID: 34722580 PMC: 8554047. DOI: 10.3389/fmed.2021.741944.

Abdominal Aortic Calcification Is a Significant Poor Prognostic Factor for Clinical Outcomes After Decompressive Laminotomy for Lumbar Spinal Canal Stenosis.

Sakaura H, Ikegami D, Fujimori T, Sugiura T, Owaki H, Fuji T Global Spine J. 2019; 9(7):724-728.

PMID: 31552153 PMC: 6745642. DOI: 10.1177/2192568219827265.

Impact of Renal Function on the Surgical Outcomes of Displaced Femoral Neck Fracture in Elderly Patients.

Kwon H, Lim S, Yang I, Lee W, Jeon B, Park K J Clin Med. 2019; 8(8).

PMID: 31374982 PMC: 6722621. DOI: 10.3390/jcm8081149.

Sakaura H, Miwa T, Yamashita T, Kuroda Y, Ohwada T Global Spine J. 2016; 6(1):2-6.

PMID: 26835195 PMC: 4733377. DOI: 10.1055/s-0035-1554774.

References

Coburn J, Maung H, Elangovan L, Germain M, Lindberg J, Sprague S . Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004; 43(5):877-90. DOI: 10.1053/j.ajkd.2004.01.012. View

Borah B, Gross G, Dufresne T, Smith T, Cockman M, Chmielewski P . Three-dimensional microimaging (MRmicroI and microCT), finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis. Anat Rec. 2001; 265(2):101-10. DOI: 10.1002/ar.1060. View

Gonzalez E, Sachdeva A, Oliver D, Martin K . Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004; 24(5):503-10. DOI: 10.1159/000081023. View

Jokihaara J, Porsti I, Pajamaki I, Vuohelainen T, Jolma P, Koobi P . Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease. J Bone Miner Res. 2006; 21(5):745-51. DOI: 10.1359/jbmr.060114. View

Miller P, Schwartz E, Chen P, Misurski D, Krege J . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2006; 18(1):59-68. DOI: 10.1007/s00198-006-0189-8. View

Takahashi F, Finch J, Denda M, Dusso A, Brown A, Slatopolsky E . A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis. 1997; 30(1):105-12. DOI: 10.1016/s0272-6386(97)90571-0. View

Ritz E, Gross M . Hyperphosphatemia in renal failure. Blood Purif. 2005; 23(1):6-9. DOI: 10.1159/000082004. View

Eisman J, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R . Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008; 35(3):488-97. View

Santos F, Moyses R, Montenegro F, Jorgetti V, Noronha I . IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int. 2003; 63(3):899-907. DOI: 10.1046/j.1523-1755.2003.00835.x. View

10.

Sprague S, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W . Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2008; 4(1):178-85. PMC: 2615694. DOI: 10.2215/CJN.02830608. View

11.

Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S . Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008; 3(4):1125-30. PMC: 2440270. DOI: 10.2215/CJN.05161107. View

12.

Seeman E, Delmas P . Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354(21):2250-61. DOI: 10.1056/NEJMra053077. View

13.

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K . Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69(11):1945-53. DOI: 10.1038/sj.ki.5000414. View

14.

Gal-Moscovici A, Sprague S . Bone health in chronic kidney disease-mineral and bone disease. Adv Chronic Kidney Dis. 2007; 14(1):27-36. DOI: 10.1053/j.ackd.2006.10.010. View

15.

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

16.

Negri A, Barone R, Quiroga M, Bravo M, Marino A, Fradinger E . Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int. 2004; 24(2):163-8. View

17.

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

18.

Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown A . A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis. 1995; 26(5):852-60. DOI: 10.1016/0272-6386(95)90455-7. View

19.

Miller P, Roux C, Boonen S, Barton I, Dunlap L, Burgio D . Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005; 20(12):2105-15. DOI: 10.1359/JBMR.050817. View

20.

Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse H . Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004; 145(7):3087-94. DOI: 10.1210/en.2003-1768. View